CDK4 and breast carcinoma: In accordance with these reported observations, BNIP3(L)-high MCF7 cells also demonstrated drug resistance to Tamoxifen, a FDA-approved drug used in ER(+) breast cancer treatment and Palbociclib, a CDK4/6 inhibitor.